On the other hand, the study indicated that the patients who received anti-CTLA-4 antibody (ipilimumab) treatment showed clinical episodes of MS, which further confirms that CTLA-4 is a treatment target for MS (178). This evidence concerns the gene CTLA4 and myeloid sarcoma.